Agno Pharma

Executive Summary

Agno Pharma is a US-based CDMO/CMO headquartered in San Diego, founded in 2019, that provides end-to-end services from API development to commercial drug product manufacturing. The company specializes in complex formulations including sterile injectables, long-acting implants, and high-potency APIs, leveraging a Quality-by-Design approach and cGMP facilities. Serving the oncology and small molecule sectors, Agno Pharma supports clients from preclinical stages through commercialization, positioning itself as a partner for innovative therapies requiring specialized manufacturing capabilities. Despite being at a pre-clinical stage as a company, its service model generates revenue from client projects, and its focus on high-demand areas like oncology and complex dosage forms offers growth potential. Agno Pharma operates in a growing market driven by the outsourcing of pharmaceutical manufacturing. The company's competitive edge lies in its expertise in handling potent compounds and complex drug delivery systems. While privately held with limited financial disclosures, its strategic location in San Diego—a biotech hub—and its state-of-the-art facilities provide a foundation for expansion. Key growth drivers include capacity expansions, new client engagements, and regulatory milestones for its manufacturing sites. The company's success hinges on its ability to secure repeat business and expand its service offerings in an increasingly competitive CDMO landscape.

Upcoming Catalysts (preview)

• Q4 2026Signing of a major long-term manufacturing agreement with a mid-size biotech70% success
• Q2 2026Completion of facility expansion for high-potency API manufacturing80% success
• H1 2027Regulatory approval for sterile injectables facility60% success